Free Trial
NASDAQ:VYGR

Voyager Therapeutics Q1 2025 Earnings Report

Voyager Therapeutics logo
$2.72 -0.10 (-3.55%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$2.68 -0.04 (-1.47%)
As of 05/30/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Voyager Therapeutics EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.35
Beat/Miss
Missed by -$0.18
One Year Ago EPS
N/A

Voyager Therapeutics Revenue Results

Actual Revenue
$6.47 million
Expected Revenue
$13.55 million
Beat/Miss
Missed by -$7.08 million
YoY Revenue Growth
N/A

Voyager Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Voyager Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Voyager Therapeutics Earnings Headlines

Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Voyager Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Voyager Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Voyager Therapeutics and other key companies, straight to your email.

About Voyager Therapeutics

Voyager Therapeutics (NASDAQ:VYGR), a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

View Voyager Therapeutics Profile

More Earnings Resources from MarketBeat